Australia, Oct. 21 -- Bristol-Myers Squibb Co., owns the trademark (2569067) for 'BYMCLIXIO' till July 22, 2035.
Status: registered:
Registered/protected
Classes: 5 [Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes.] and 5 [Pharmaceutical preparations for the treatment and prevention of oncological, hematological, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders;stem cells for medical purposes;diagnostic radiopharmaceutical preparations;diagnostic preparations for medical purposes;radiopharmaceutical preparations for the treatment of cancer and immune system related diseases and disorders]
Type of Mark: Word
Date of Acceptance: Aug. 5
Registration Advertised: Oct. 20
For further details contact Spruson & Ferguson.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2569067.
Disclaimer: Curated by HT Syndication.
